首页> 外文期刊>The Journal of Urology >Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup.
【24h】

Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup.

机译:膀胱移行细胞癌根治性膀胱切除术后上尿路尿道上皮复发:对1069例随访10年的患者进行分析。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: Risk factors for upper tract recurrence following radical cystectomy for transitional cell carcinoma of the bladder are not yet well-defined. We reviewed our population of patients who underwent radical cystectomy to identify prognostic factors and clinical outcomes associated with upper tract recurrence. MATERIALS AND METHODS: From our prospective database of 1,359 patients who underwent radical cystectomy we identified 1,069 patients treated for transitional cell carcinoma of the bladder between January 1985 and December 2001. Univariate analysis was completed to determine factors predictive of upper tract recurrence. RESULTS: A total of 853 men and 216 women were followed for a median of 10.3 years (maximum 18.5). There were 27 (2.5%) upper tract recurrences diagnosed at a median of 3.3 years (range 0.4 to 9.3). Only urethral tumor involvement was predictive of upper tract recurrence. In men superficial transitional cell carcinoma of the prostatic urethra was associated with an increased risk of upper tract recurrence compared with prostatic stromal invasion or absence of prostatic transitional cell carcinoma (p <0.01). In women urethral transitional cell carcinoma was associated with an increased risk of upper tract recurrence (p = 0.01). Despite routine surveillance 78% of upper tract recurrence was detected after development of symptoms. Median survival following upper tract recurrence was 1.7 years (range 0.2 to 8.8). Detection of asymptomatic upper tract recurrence via surveillance did not predict lower nephroureterectomy tumor stage, absence of lymph node metastases or improved survival. CONCLUSIONS: Patients with bladder cancer are at lifelong risk for late oncological recurrence in the upper tract urothelium. Patients with evidence of tumor involvement within the urethra are at highest risk. Surveillance regimens frequently fail to detect tumors before symptoms develop. However, radical nephroureterectomy can provide prolonged survival.
机译:目的:根治性膀胱切除术治疗膀胱移行细胞癌后上消化道复发的危险因素尚未明确。我们回顾了行根治性膀胱切除术的患者人群,以鉴定与上段复发相关的预后因素和临床结果。材料与方法:从我们的1359例行根治性膀胱切除术的患者的前瞻性数据库中,我们确定了1,069例在1985年1月至2001年12月之间接受治疗的膀胱移行细胞癌患者。完成了单因素分析,以确定预测上段复发的因素。结果:总共853名男性和216名女性被随访,中位数为10.3年(最大18.5岁)。被诊断出27例(2.5%)上尿道复发,中位数为3.3年(范围0.4至9.3)。仅尿道肿瘤受累可预测上段复发。在男性中,与前列腺间质浸润或不存在前列腺移行细胞癌相比,前列腺尿道浅表移行细胞癌的患上尿道复发的风险增加(p <0.01)。在女性中,尿道移行细胞癌与上尿道复发的风险增加相关(p = 0.01)。尽管进行了常规监测,但症状出现后仍有78%的上消化道复发被发现。上路复发后的中位生存期为1.7年(范围为0.2至8.8)。通过监测发现无症状上段复发不能预测下肾切除术的肿瘤分期,无淋巴结转移或生存率的提高。结论:膀胱癌患者在上尿路上皮癌中有晚期肿瘤复发的终生风险。有尿道内肿瘤累及迹象的患者风险最高。监测方案常常在症状出现之前无法检测到肿瘤。但是,根治性肾切除术可以延长生存期。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号